Exciting times are ahead in the field of Frontotemporal Dementia (FTD) research! For the first time, a Phase 3 trial has concluded for a potential disease-altering treatment targeting a genetic form of FTD, with results expected as soon as 2025.

As we eagerly anticipate these results, let’s dive into the latest updates on various ongoing trials focusing on genetic FTD, which could pave the way for advancements benefiting all FTD patients, healthcare professionals, and investors alike.

Currently, an estimated 40% of FTD cases have a genetic basis, sparking intense research centered around the progranulin hypothesis. This theory posits that by restoring levels of progranulin—especially in patients with GRN genetic variations—we may alleviate the symptoms and progression of FTD.

While there are significant genes like C9orf72 and MAPT also linked to FTD, we’re focusing on the GRN gene, which is leading the charge in clinical trials. Moreover, ongoing research into related conditions like ALS and Alzheimer’s may unveil breakthroughs applicable to various forms of FTD.

Current Clinical Trials Overview